| Oct 24 |
Compass Pathways to Announce Third Quarter Financial Results on October 31, 2024
|
| Oct 19 |
FDA is said to see “path forward” for ecstasy-based drug
|
| Oct 7 |
COMPASS Pathways files for mixed shelf offering
|
| Sep 26 |
Psilocybin Breakthrough: Study Reveals Potential Application For Body Dysmorphic Disorder
|
| Sep 23 |
Compass Pathways to Participate in Cowen Psychedelics and Novel Mechanisms in Neuropsychiatry Summit
|
| Sep 13 |
MDMA Therapy For PTSD Faces FDA Delay: Are There Other Ways Forward?
|
| Sep 5 |
Shake Up At Lykos Therapeutics After FDA Blocks Ecstasy-Based Treatment, CEO Steps Down
|
| Aug 30 |
Compass Therapeutics files $300M mixed securities shelf
|
| Aug 28 |
Compass Pathways to participate in three investor conferences in September
|
| Aug 25 |
Morgan Stanley Predicts up to 220% Jump for These 2 ‘Strong Buy’ Stocks
|
